Testing adebrelimab, apatinib, and HAIC for bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of intrahepatic cholangiocarcinoma (a type of bile duct cancer) that can be removed with surgery.
- Your cancer is at stage Ib to IIIb (spread within the liver but not to distant organs).
- You are 18 years or older.
- You are in good physical condition (ECOG score 0 or 1, meaning you are fully active or able to do light work).
- Your blood work and organ function meet certain safety levels (like enough white blood cells, normal kidney and liver function).
- You have not had any previous treatment for this tumor (except if you had surgery for bile duct cancer at least 2 years ago and it came back).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (lenvatinib), an immunotherapy (PD-1 inhibitor), and chemotherapy given directly into the liver's blood supply for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer that starts in the liver). The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests a new combination of three drugs (adebrelimab, surufatinib, and liposomal irinotecan) given directly into the liver artery for advanced intrahepatic cholangiocarcinoma. The goal is to see if this approach can shrink or control the cancer.
This trial tests combining two drugs (adebrelimab and lenvatinib) with a liver-directed chemotherapy infusion (HAIC) to shrink locally advanced bile duct or gallbladder cancers enough to allow surgery. It is for people who haven't had prior treatment for their biliary cancer and whose cancer has not spread far.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.